1 min read
Add as a preferred source on GoogleTRex Bio Prices IPO at $14, Targets $117 Million Gross
The clinical-stage biotechnology company is offering 8.33 million shares and expects approximately $116.7 million in gross proceeds.
TRex Bio, Inc. (TRXB) set its initial public offering price at $14 per share, with the clinical-stage biotechnology company seeking approximately $116.7 million in gross proceeds.
The offering covers 8.33 million shares. TRex Bio develops immunoregulatory medicines.
The company’s stock is expected to begin trading on Nasdaq Global.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.